Experimental drug ARRY-614 paired with immunotherapy shows promise in early cancer trial
NCT ID NCT04074967
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called ARRY-614 combined with standard immunotherapies (nivolumab or nivolumab plus ipilimumab) in people with advanced solid tumors, including lung, head and neck, kidney, and skin cancers. The first part of the trial finds the safest dose, and the second part checks whether the combination shrinks tumors. About 70 participants are enrolled, and the goal is to see if this approach can help when other treatments have stopped working.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ARRY-614 (an experimental drug) combined with nivolumab or nivolumab plus ipilimumab (immunotherapies)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced cancers like lung, head and neck, kidney, or skin cancer that hasn't responded to other therapies.
- What could go wrong
- This is an early-phase trial with only 70 participants, so results are preliminary. The drug combination may cause serious side effects, and it's unknown if it will effectively shrink tumors or improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a radioactive tracer reveal whether immunotherapy is working?
- Can a new nucleotide analogue boost cancer treatment?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can a blast of radiation make immunotherapy work better against kidney cancer?
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?